The post Attorney Jennifer Ball Presents at Warwick Legal Network Conference appeared first on Morningstar Law Group.

Jenn is a Raleigh attorney with a background in biology and a lifelong interest in innovation. She advises life sciences and healthcare companies on a range of regulatory and transactional matters, including licensing agreements, product development, and strategic growth initiatives. Known for her ability to simplify complex legal and technical issues, Jenn provides tailored, pragmatic counsel that aligns with each client’s goals and stage of development.

Her industry insight comes from years of in-house legal roles at leading life sciences and healthcare organizations — including Syngenta, where she worked on global R&D, licensing, and M&A matters, as well as leadership roles at a clinical research organization, a pharmaceutical manufacturer, a gene therapy company, and a metabolomics lab. This hands-on experience gives her a deep appreciation of how innovative companies operate and the regulatory challenges they face.

Jenn began her legal career in Delaware, advising business entities at one of the state’s largest firms, and later worked with North Carolina startups through a boutique practice focused on early-stage company formation, funding, and exit strategy.

We’re excited to have Jenn on board and know our clients will benefit from her thoughtful, business-minded approach to regulatory and transactional counsel.

The post Morningstar Law Group Welcomes Attorney Jennifer Ball to FDA & Healthcare Regulatory Practice appeared first on Morningstar Law Group.

Wood explains that the hard-fought agreement, based on claims that Purdue Pharma sales of OxyContin played a major role in creating the U.S. opioid crisis, brought together all 50 states and thousands of other public entity-claimants to provide nearly $7 billion in much-needed relief to help local communities across the country fight the opioid epidemic.

The Supreme Court’s 5-4 decision to throw out the Purdue settlement threatens to turn $7 billion in desperately needed relief into nearly nothing.

Claimants will now face formidable obstacles to effectively pursue the Sacklers individually. Even if a substantial collective recovery is somehow achieved, thousands of people who could have been helped will suffer – and some will die – during the time it takes for those efforts to play out.

Read the entire article HERE.

Article By:

The post Swain Wood: SCOTUS’s decision to throw out the Purdue Pharma settlement agreement was a profound mistake. appeared first on Morningstar Law Group.

The post Ben Martie to Join Panel Discussion of “The FDA’s Role in Regenerative Healthcare” appeared first on Morningstar Law Group.

Morningstar Law Group is extremely pleased to announce that attorneys Hank Gates and Ben Martie were recently invited to join the partnership. Both attorneys exemplify our core value of being client-focused. We look forward to their years of continued excellence in law practice and tireless dedication to their clients and colleagues. We are proud of you and so glad you are part of the Morningstar Law Group team.

Hank joined our firm in 2018 and has worked as an associate attorney in our Durham, NC office and our litigation and employment practice groups.

Ben joined Morningstar Law Group in 2023 after serving as in-house counsel with privately held and publicly traded pharmaceutical and life sciences companies in the Triangle for over a decade. He works in our Raleigh, NC office and is spearheading the growth of our FDA and Healthcare Regulatory practice group.

The post Congratulations to Hank Gates and Ben Martie, Welcome to the Partnership! appeared first on Morningstar Law Group.

We have exciting news to share! After serving the pharma and biotech verticals for the past decade, we are leveraging our expansion of talent and services to create our newest practice area – FDA and Healthcare Regulatory. Ben Martie, who joined Morningstar Law Group in 2022 with over ten years of experience in the pharma industry, including as in-house counsel and compliance officer, shares our excitement, “Over the last year, the firm has significantly expanded its capabilities and support for FDA-regulated businesses, such as pharmaceutical, biotech, and medical device companies and CDMOs.  Today, I am delighted to announce the formal launch of the FDA and Healthcare Regulatory practice group at Morningstar.  With this addition, the firm further demonstrates its tireless commitment to FDA-regulated businesses and the patients they serve.  As the firm’s work continues, I know its efforts in this space will also, and I am excited for the road ahead.”

To learn more about the FDA and Healthcare Regulatory team and services offered, visit the practice area’s home on our website HERE.

The post Announcing Our Newest Practice Area – FDA and Healthcare Regulatory appeared first on Morningstar Law Group.